Lassa Viral Transmission and Immunoprotection: Defective Interfering Particles (DIPs) in Carrier Rodents and Lassa Virus-Infected People

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 473816

Grant search

Key facts

  • Disease

    Lassa Haemorrhagic Fever
  • start year

    2022
  • Known Financial Commitments (USD)

    $109,655.17
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principal Investigator

    Nadesalingam Angalee
  • Research Location

    Belize
  • Lead Research Institution

    Broad Institute of MIT and Harvard (Cambridge, MA)
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The World Health Organization lists Lassa virus (LASV) as one of the of top 10 pathogens with high epidemic potential. LASV is currently endemic to West Africa, infecting up to 500,000 people, annually. It causes Lassa fever (LF) with symptoms ranging from malaise/deafness to haemorrhaging through all orifices. LASV can be as dangerous as Ebola and SARS-CoV-2. About 20% of LASV-infected people develop disease that can severely damage the brain, liver, spleen, kidney and other vital organs. Hospital fatality of LF patients can be as high as 69%. But, the reasons why LASV-infected people mount such varying immune responses are not understood. LASV is transmitted to humans mainly through the aerosols of urine/faeces of rodents. As an RNA virus, it has an inaccurate system of replication. 'Errors' in replication can lead to the production of defective interfering viral particles (DIPs) that are known to modulate immune response, in other RNA viruses. DIPs are present in LASV-infected mice, but their relevance in LF in humans is unknown. Therefore, during my Fellowship, I will determine whether (i) DIP levels vary between rodent species and modify transmissibility to humans, and how (ii) DIPs modulate immune responses in LASV-infected people, and regulate disease severity in LF patients. DIPs will be measured in rodent urine, faeces and tissue to understand how individuals in endemic areas are exposed to Lassa antigens. DIPs and antibodies in the patients' blood will be studied to reveal their role in disease progression and immunity. Because DIPs stimulate immune response without causing infection, DIPs are considered as vaccine candidates (e.g., Ebola, SARS-CoV-2, Dengue, Zika). No satisfactory treatment or vaccine is available to fight against LF. Hence, understanding LASV transmission and immunogenicity via a One Health approach, and identifying novel LASV vaccine candidates and diagnostic approaches are of paramount importance to prevent a LF pandemic.